Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Tougeron

Showing results (111-120 of 235) with videos related to

Pageof 24
Sort By:
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 13, 2024
Chemoradiotherapy versus radiotherapy alone in the management of early-stage anal squamous cell carcinoma: A comparative analysis of the French cohort FFCD-ANABASEChloé Buchalet, Claire Lemanski, Pascal Pommier, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 28, 2020
Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trialJulien Taïeb, Thierry André, Farid El Hajbi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2023
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line settingBahar Saberzadeh-Ardestani, Jeremy C Jones, Robert R McWilliams, et al.
Frontiers in Genetics|January 20, 2022
HSP110 as a Diagnostic but Not a Prognostic Biomarker in Colorectal Cancer With Microsatellite InstabilityGaelle Tachon, Arnaud Chong-Si-Tsaon, Thierry Lecomte, et al.
Clinics and Research in Hepatology and Gastroenterology|December 18, 2025
Switch from cetuximab to panitumumab during encorafenib-based therapy in BRAF V600E mutated metastatic colorectal cancer: An international multicenter analysis from the AGEO groupAnnalice Gandini, Victoria Probst, Matteo Landi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancerMargherita Ambrosini, Claire Gallois, Annalice Gandini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 2, 2023
Prognostic score for synchronous metastatic rectal cancer: A real-world studyLéa Muzellec, Loïc Campion, Jean-Baptiste Bachet, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2020
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trialAlice Boilève, Marc Hilmi, Paul Gougis, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic CholangiocarcinomasCamille Goislard de Monsabert, Yann Touchefeu, Boris Guiu, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 14, 2022
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49Simon Pernot, Olivier Pellerin, Laurent Mineur, et al.
Pageof 24

Showing results (111-120 of 235) with videos related to

Sort By:
Pageof 24
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 13, 2024
Chemoradiotherapy versus radiotherapy alone in the management of early-stage anal squamous cell carcinoma: A comparative analysis of the French cohort FFCD-ANABASEChloé Buchalet, Claire Lemanski, Pascal Pommier, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 28, 2020
Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trialJulien Taïeb, Thierry André, Farid El Hajbi, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2023
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line settingBahar Saberzadeh-Ardestani, Jeremy C Jones, Robert R McWilliams, et al.
Frontiers in Genetics|January 20, 2022
HSP110 as a Diagnostic but Not a Prognostic Biomarker in Colorectal Cancer With Microsatellite InstabilityGaelle Tachon, Arnaud Chong-Si-Tsaon, Thierry Lecomte, et al.
Clinics and Research in Hepatology and Gastroenterology|December 18, 2025
Switch from cetuximab to panitumumab during encorafenib-based therapy in BRAF V600E mutated metastatic colorectal cancer: An international multicenter analysis from the AGEO groupAnnalice Gandini, Victoria Probst, Matteo Landi, et al.
European Journal of Cancer (Oxford, England : 1990)|April 8, 2026
From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancerMargherita Ambrosini, Claire Gallois, Annalice Gandini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 2, 2023
Prognostic score for synchronous metastatic rectal cancer: A real-world studyLéa Muzellec, Loïc Campion, Jean-Baptiste Bachet, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2020
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trialAlice Boilève, Marc Hilmi, Paul Gougis, et al.
Current Oncology (Toronto, Ont.)|December 13, 2021
Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic CholangiocarcinomasCamille Goislard de Monsabert, Yann Touchefeu, Boris Guiu, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 14, 2022
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49Simon Pernot, Olivier Pellerin, Laurent Mineur, et al.
Pageof 24